

**For Immediate Release**TSX Exchange Symbol: **RVX****Resverlogix Corp. Expands NexVas™ ApoA-I Program  
Into Stroke**

CALGARY, AB, May 4, 2006 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX), is pleased to announce today it will expand its research and development program for its lead technology NexVas™ into Stroke. The objective of this expansion is to address the crippling disease of Stroke and to fully develop the commercial opportunity for the company’s current product pipeline in ApoA-1 enhancement therapies.

Stroke is the third leading cause of death in the industrialized world. Every 40 seconds someone in North America has a stroke. Accordingly to the 2006 Report from the American Heart & Stroke Association the cost and burden of Stroke was estimated at \$58 billion USD.

In the landmark clinical trial, AMORIS, over 175,000 patients with cardiovascular risk factors were studied with special focus on incidence of cardiac and stroke events. AMORIS clearly illustrated that the improvement of levels of ApoA-I to Apo B led to dramatic reduction of stroke in this population. The key findings of this study indicated that improvement of 'cholesterol balance', or ApoA-1 to ApoB ratio is a robust and specific maker of virtually all ischemic events.

“The addition of Stroke into our NexVas™ program brings an important strategic asset to our company” stated Dr. Jan Johansson, Senior Vice President of Clinical Affairs at Resverlogix. “Expanding upon our NexVas™ technology program into Stroke will continue to position the company as a leader in the management of atherosclerosis, the major underlying cause of cardiovascular disease”.

“A major goal of our NexVas™ business strategy is to build a portfolio of therapies for vascular diseases that focus on multiple CVD indications” stated Kenneth Lebioda, Vice President of Business & Market Development. “Our compounds continue to illustrate very positive effects in enhancing ApoA-I levels. Having clear clinical evidence in landmark trials such as AMORIS, again validates enhanced ApoA-I levels role in reducing and preventing major adverse vascular events such as stroke. This provides us another important commercial opportunity that we will fully explore and continue to build synergies upon for our NexVas™ program,” Mr. Lebioda added.

**About Resverlogix Corp.**

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix’s lead technology NexVas™, applies advanced medical research to develop therapies that increase ApoA-1 the key protein of high density lipoprotein (HDL), the "good cholesterol," and other targets to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: [www.resverlogix.com](http://www.resverlogix.com).

*This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.*

**For further information please contact:**

**Donald J. McCaffrey**  
President/CEO

Resverlogix Corp.  
Phone: 403-254-9252 ext. 223  
Fax: 403-256-8495  
Email: [don@resverlogix.com](mailto:don@resverlogix.com)

**Kenneth Lebioda**  
Vice President Business Development

Resverlogix Corp.  
Phone: 403-254-9252 ext. 227  
Fax: 403-256-8495  
Email: [ken@resverlogix.com](mailto:ken@resverlogix.com)

Website: [www.resverlogix.com](http://www.resverlogix.com)